BlackRock Inc. Takes Position in Crescent Biopharma, Inc. $CBIO

Posted by George Bondi on Sep 3rd, 2026

BlackRock Inc. purchased a new stake in Crescent Biopharma, Inc. (NASDAQ:CBIO – Free Report) in the 2nd quarter, HoldingsChannel reports. The firm purchased 1,271,762 shares of the biopharmaceutical company’s stock, valued at approximately $22,892,000.

A number of other large investors also recently bought and sold shares of CBIO. OMERS ADMINISTRATION Corp acquired a new position in Crescent Biopharma in the 4th quarter valued at $138,000. Bank of America Corp DE acquired a new stake in Crescent Biopharma during the 2nd quarter worth $149,000. HRT Financial LP acquired a new stake in Crescent Biopharma during the 4th quarter worth $155,000. Quadrature Capital Ltd purchased a new stake in shares of Crescent Biopharma during the fourth quarter worth $157,000. Finally, Cannon Global Investment Management LLC purchased a new stake in shares of Crescent Biopharma during the first quarter worth $187,000. Institutional investors and hedge funds own 75.19% of the company’s stock.

Insider Activity

In other news, COO Jonathan Mcneill sold 20,549 shares of the business’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $17.99, for a total transaction of $369,676.51. Following the transaction, the chief operating officer owned 139,158 shares of the company’s stock, valued at approximately $2,503,452.42. The trade was a 12.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Joshua T. Brumm sold 42,305 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $17.99, for a total transaction of $761,066.95. Following the completion of the sale, the chief executive officer directly owned 281,212 shares of the company’s stock, valued at $5,059,003.88. This represents a 13.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 68,156 shares of company stock worth $1,226,126. Corporate insiders own 24.84% of the company’s stock.

Crescent Biopharma Stock Performance

Shares of Crescent Biopharma stock opened at $18.54 on Thursday. The business’s 50 day moving average price is $16.65 and its 200 day moving average price is $16.78. The company has a market cap of $688.58 million, a price-to-earnings ratio of -2.76 and a beta of 1.24. Crescent Biopharma, Inc. has a one year low of $8.72 and a one year high of $27.41.

Crescent Biopharma (NASDAQ:CBIO – Get Free Report) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.74). On average, analysts predict that Crescent Biopharma, Inc. will post -2.91 EPS for the current fiscal year.

Analysts Set New Price Targets

CBIO has been the subject of a number of recent research reports. TD Cowen upgraded shares of Crescent Biopharma to a “strong-buy” rating in a research report on Monday, August 24th. HC Wainwright restated a “neutral” rating on shares of Crescent Biopharma in a research report on Thursday, July 16th. Wedbush reaffirmed an “outperform” rating and set a $27.00 price objective on shares of Crescent Biopharma in a research note on Thursday, August 27th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Crescent Biopharma in a report on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Crescent Biopharma has a consensus rating of “Moderate Buy” and an average target price of $29.60.

Check Out Our Latest Stock Report on Crescent Biopharma

Crescent Biopharma Profile

(Free Report)

Crescent Biopharma, Inc (NASDAQ: CBIO) is a clinical‐stage immuno‐oncology company focused on the discovery, development and commercialization of novel therapies for patients with solid tumors. The company’s research strategy centers on combination approaches that enhance anti‐tumor immune responses by simultaneously targeting multiple pathways implicated in immune evasion and tumor growth.

The company’s lead candidate, CPB-201, is a bifunctional fusion protein designed to block programmed death-ligand 1 (PD-L1) while neutralizing transforming growth factor-beta (TGF-β), with the goal of restoring T-cell activity and reducing tumor fibrosis.